JP2022511348A5 - - Google Patents

Info

Publication number
JP2022511348A5
JP2022511348A5 JP2021516750A JP2021516750A JP2022511348A5 JP 2022511348 A5 JP2022511348 A5 JP 2022511348A5 JP 2021516750 A JP2021516750 A JP 2021516750A JP 2021516750 A JP2021516750 A JP 2021516750A JP 2022511348 A5 JP2022511348 A5 JP 2022511348A5
Authority
JP
Japan
Application number
JP2021516750A
Other languages
Japanese (ja)
Other versions
JP2022511348A (ja
JP7560447B2 (ja
JPWO2020086881A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/057916 external-priority patent/WO2020086881A1/en
Publication of JP2022511348A publication Critical patent/JP2022511348A/ja
Publication of JP2022511348A5 publication Critical patent/JP2022511348A5/ja
Publication of JPWO2020086881A5 publication Critical patent/JPWO2020086881A5/ja
Priority to JP2024161633A priority Critical patent/JP2025000711A/ja
Application granted granted Critical
Publication of JP7560447B2 publication Critical patent/JP7560447B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021516750A 2018-10-25 2019-10-24 Aavトリプルプラスミドシステム Active JP7560447B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024161633A JP2025000711A (ja) 2018-10-25 2024-09-19 Aavトリプルプラスミドシステム

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862750603P 2018-10-25 2018-10-25
US62/750,603 2018-10-25
PCT/US2019/057916 WO2020086881A1 (en) 2018-10-25 2019-10-24 Aav triple-plasmid system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024161633A Division JP2025000711A (ja) 2018-10-25 2024-09-19 Aavトリプルプラスミドシステム

Publications (4)

Publication Number Publication Date
JP2022511348A JP2022511348A (ja) 2022-01-31
JP2022511348A5 true JP2022511348A5 (https=) 2022-10-19
JPWO2020086881A5 JPWO2020086881A5 (https=) 2022-10-19
JP7560447B2 JP7560447B2 (ja) 2024-10-02

Family

ID=70331899

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021516750A Active JP7560447B2 (ja) 2018-10-25 2019-10-24 Aavトリプルプラスミドシステム
JP2024161633A Pending JP2025000711A (ja) 2018-10-25 2024-09-19 Aavトリプルプラスミドシステム

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024161633A Pending JP2025000711A (ja) 2018-10-25 2024-09-19 Aavトリプルプラスミドシステム

Country Status (10)

Country Link
US (1) US12383587B2 (https=)
EP (1) EP3870148A4 (https=)
JP (2) JP7560447B2 (https=)
KR (1) KR20210086645A (https=)
CN (1) CN112888426A (https=)
AU (1) AU2019363593A1 (https=)
CA (1) CA3112883A1 (https=)
IL (1) IL281909A (https=)
TW (1) TW202029957A (https=)
WO (1) WO2020086881A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144061A1 (en) 2018-01-19 2019-07-25 Duke University Genome engineering with crispr-cas systems in eukaryotes
US10557149B1 (en) * 2019-07-15 2020-02-11 Vigene Biosciences, Inc. Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus
EP4189077A1 (en) 2020-07-30 2023-06-07 Shape Therapeutics Inc. Stable cell lines for inducible production of raav virions
WO2022087321A1 (en) * 2020-10-21 2022-04-28 Duke University Dual aav vector-mediated deletion of large mutational hotspot for treatment of duchenne muscular dystrophy
IL302578A (en) * 2020-11-04 2023-07-01 Synplogen Co Ltd Production of a virus vector plasmid in Bacillus Subtilis
US11926842B2 (en) * 2021-02-02 2024-03-12 University Of Massachusetts Use of inverted terminal repeats (ITRS) from adeno-associated virus serotypes 8 and RH.39 in gene therapy vectors
US20240360422A1 (en) * 2021-04-21 2024-10-31 Michael T. Leonard Stable production systems for adeno-associated virus production
US12305188B2 (en) 2021-05-27 2025-05-20 Neuracle Genetics Inc. Dual helper plasmid
KR102685652B1 (ko) * 2021-05-27 2024-07-19 주식회사 뉴라클제네틱스 신규한 듀얼 헬퍼 플라스미드
EP4377471A4 (en) * 2021-07-28 2025-10-15 Atsena Therapeutics Inc AAV TRANSFER PLASMIDS
CN114196705B (zh) * 2021-12-07 2024-09-06 中国科学院深圳先进技术研究院 一种重组腺相关病毒包装质粒、重组腺相关病毒及其应用
WO2023102736A1 (zh) * 2021-12-07 2023-06-15 中国科学院深圳先进技术研究院 一种重组腺相关病毒包装质粒、重组腺相关病毒及其应用
KR20250009975A (ko) * 2022-05-12 2025-01-20 아브너진 인코포레이티드 재조합 파르보바이러스 생산을 위한 조성물 및 방법
CN119866377A (zh) * 2022-08-31 2025-04-22 镇江蓬勃生物科技有限公司 能够提高腺相关病毒滴度的腺相关病毒结构质粒
CN116064672B (zh) * 2022-09-15 2025-02-14 思鹏生物科技(苏州)有限公司 利用ires基因提升aav包装效率的方法及其功能基因
WO2024098035A2 (en) * 2022-11-04 2024-05-10 National Resilience, Inc. Methods and compositions for preparing recombinant adeno associated viruses and uses thereof
WO2024160232A1 (zh) * 2023-02-01 2024-08-08 纽福斯(苏州)生物科技有限公司 质粒包装系统及其应用
CN116411024A (zh) * 2023-03-10 2023-07-11 上海泰昶生物技术有限公司 用于生产重组腺相关病毒的质粒系统
US20240352483A1 (en) * 2023-04-03 2024-10-24 Decibel Therapeutics, Inc. Modified rep-cap plasmids and uses thereof
WO2024238742A2 (en) * 2023-05-16 2024-11-21 Oxford Biomedica (Us) Llc Compositions and methods for increasing aav productivity
WO2025050347A1 (en) * 2023-09-07 2025-03-13 Chigenovo Co., Ltd. Aav vector backbone optimization and use thereof
CN117683797B (zh) * 2023-12-04 2024-07-05 广州派真生物技术有限公司 一种用于重组腺相关病毒包装的质粒系统及其应用
CN117925663A (zh) * 2023-12-04 2024-04-26 广州派真生物技术有限公司 一种用于重组腺相关病毒包装的质粒系统及其应用
CN117778431B (zh) * 2023-12-04 2024-10-25 广州派真生物技术有限公司 一种用于重组腺相关病毒包装的质粒系统及其应用
CN121780618A (zh) * 2023-12-13 2026-04-03 广州派真生物技术有限公司 一种高产重组腺相关病毒的辅助质粒及应用
CN117660534B (zh) * 2023-12-13 2024-05-07 广州派真生物技术有限公司 一种降低重组腺相关病毒中宿主细胞dna残留的辅助质粒及应用
US20250276095A1 (en) 2024-03-04 2025-09-04 Kate Therapeutics, Inc. Adeno-associated virus compositions for the treatment of duchenne muscular dystrophy
WO2025217308A1 (en) * 2024-04-10 2025-10-16 Solid Biosciences Inc. Method of aav production
WO2025226842A1 (en) 2024-04-24 2025-10-30 Kate Therapeutics, Inc. Expression control by drg-expressed mirnas
WO2025226841A1 (en) 2024-04-24 2025-10-30 Kate Therapeutics, Inc. Gene therapy approach for treating disorders associated with tnnt2
WO2026011008A1 (en) 2024-07-02 2026-01-08 Kate Therapeutics, Inc. Expression control by skeletal muscle-expressed mirnas
WO2026011009A1 (en) 2024-07-02 2026-01-08 Kate Therapeutics, Inc. Compositions and methods for muscle disorders
WO2026030242A1 (en) 2024-07-29 2026-02-05 Kate Therapeutics, Inc. Adeno-associated virus compositions for the treatment of facioscapulohumeral muscular dystrophy
WO2026030244A1 (en) 2024-07-30 2026-02-05 Kate Therapeutics, Inc. Adeno-associated virus compositions for the treatment of limb girdle muscular dystrophy 2a
WO2026050402A1 (en) 2024-08-29 2026-03-05 Kate Therapeutics, Inc. Liver de-targeted muscle tropic capsids
CN119662733B (zh) * 2024-12-09 2025-10-28 广州派真生物技术有限公司 一种高产rAAV的质粒系统及应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004797A (en) 1995-11-09 1999-12-21 Avigen, Inc. Adenovirus helper-free recombinant AAV Virion production
CA2369985A1 (en) 2002-01-18 2003-07-18 Duke University Generation of recombinant adeno-associated viral vectors by a complete adenovirus-mediated approach
US9249425B2 (en) 2011-05-16 2016-02-02 The Trustees Of The University Of Pennslyvania Proviral plasmids and production of recombinant adeno-associated virus
US9163259B2 (en) * 2012-05-04 2015-10-20 Novartis Ag Viral vectors for the treatment of retinal dystrophy
MX384795B (es) * 2013-03-15 2025-03-14 Childrens Hospital Philadelphia Vectores que comprenden secuencias de polinucleotidos rellenadoras/de relleno y metodos de uso.
KR20240090694A (ko) 2013-07-22 2024-06-21 더 칠드런스 호스피탈 오브 필라델피아 변종 aav 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도
EP3039129B1 (en) 2013-08-30 2018-06-27 Amgen Inc. High titer recombinant aav vector production in adherent and suspension cells
CN105765066B (zh) 2013-11-29 2018-12-14 宝生物工程株式会社 用于定量腺伴随病毒的方法
AU2015229464B2 (en) * 2014-03-11 2021-07-22 Wayne State University A modified mGluR6 promoter and methods of use
WO2016074016A1 (en) 2014-11-10 2016-05-19 Murdoch Childrens Research Institute Vectors and methods for targeted integration in loci comprising constitutively expressed genes
RS63416B1 (sr) 2015-03-03 2022-08-31 Fond Telethon Sistem višestrukih vektora i njegove primene
WO2016183422A1 (en) 2015-05-14 2016-11-17 St. Jude Children's Research Hospital, Inc. Nucleic acid molecules containing spacers and methods of use thereof
US11027024B2 (en) 2015-05-29 2021-06-08 University Of Iowa Research Foundation Methods of delivery of transgenes for treating brain diseases
KR102445192B1 (ko) 2016-10-31 2022-09-20 코오롱생명과학 주식회사 통증 완화 또는 치료용 조성물
JP2021520232A (ja) 2018-04-05 2021-08-19 オックスフォード ユニバーシティ イノベーション リミテッドOxford University Innovation Limited 黄斑ジストロフィーを処置するための組成物及び方法

Similar Documents

Publication Publication Date Title
JP2022511348A5 (https=)
BR112019017762A2 (https=)
BR112021017339A2 (https=)
BR112021018450A2 (https=)
BR112021017637A2 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
BR112021016821A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021016996A2 (https=)
BR112021008711A2 (https=)
BR112019016141A2 (https=)
BR112021017728A2 (https=)
AU2020104490A5 (https=)
BR112021013944A2 (https=)
BR112021018452A2 (https=)
BR112021017703A2 (https=)
BR112021018102A2 (https=)
BR112019016142A2 (https=)
BR112019016138A2 (https=)
BR112021017732A2 (https=)
BR112021017234A2 (https=)
BR112021017355A2 (https=)
BR112021018168A2 (https=)